GH Research PLCNASDAQ:GHRS
- LAST PRICE9.2800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots8.5000/ 1
- Ask / Lots12.0000/ 1
- Open / Previous Close--- / 9.2800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GHRS |
|---|---|---|
| 09:32 ET | 682 | 9.16 |
| 09:33 ET | 2300 | 9.36 |
| 09:35 ET | 300 | 9.1 |
| 09:42 ET | 100 | 8.97 |
| 09:44 ET | 300 | 9.03 |
| 09:46 ET | 500 | 9.025 |
| 09:48 ET | 250 | 9.025 |
| 09:50 ET | 350 | 9.025 |
| 09:51 ET | 400 | 9.05 |
| 09:57 ET | 3465 | 9.025 |
| 10:00 ET | 300 | 9.19 |
| 10:02 ET | 400 | 8.9916 |
| 10:06 ET | 100 | 9.125 |
| 10:08 ET | 200 | 9.01 |
| 10:09 ET | 1200 | 9.23 |
| 10:13 ET | 900 | 9.275 |
| 10:20 ET | 571 | 9.275 |
| 10:24 ET | 2050 | 9.1 |
| 10:26 ET | 200 | 9.03 |
| 11:03 ET | 100 | 8.875 |
| 11:12 ET | 106 | 8.88 |
| 11:27 ET | 1725 | 8.77 |
| 11:30 ET | 200 | 8.7101 |
| 11:32 ET | 200 | 8.71 |
| 11:41 ET | 500 | 8.835 |
| 11:50 ET | 1700 | 8.84 |
| 12:15 ET | 110 | 8.67 |
| 12:32 ET | 500 | 8.7994 |
| 01:15 ET | 100 | 8.8 |
| 01:20 ET | 5100 | 8.74 |
| 01:22 ET | 5186 | 8.81 |
| 01:24 ET | 4200 | 8.85 |
| 01:26 ET | 100 | 8.9 |
| 01:36 ET | 200 | 8.82 |
| 01:47 ET | 700 | 8.85 |
| 01:54 ET | 800 | 8.82 |
| 01:56 ET | 500 | 9.0925 |
| 01:58 ET | 3622 | 8.87 |
| 02:00 ET | 1400 | 8.89 |
| 02:02 ET | 1500 | 9.117369 |
| 02:05 ET | 503 | 8.91 |
| 02:09 ET | 325 | 9.06 |
| 02:14 ET | 2914 | 8.835 |
| 02:16 ET | 2810 | 8.925 |
| 02:21 ET | 100 | 8.99 |
| 02:25 ET | 100 | 8.85 |
| 02:39 ET | 200 | 8.92 |
| 02:43 ET | 100 | 8.91 |
| 03:01 ET | 100 | 8.92 |
| 03:14 ET | 100 | 8.91 |
| 03:17 ET | 100 | 8.905 |
| 03:19 ET | 100 | 8.905 |
| 03:35 ET | 206 | 9 |
| 03:48 ET | 100 | 8.965 |
| 03:53 ET | 200 | 9.01 |
| 04:00 ET | 747 | 9.28 |
Nov 20, 2024
DJ GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co., from 5:05AM ET on Wednesday Nov 20, 2024 by Dow Jones
5:05AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
DJ GH Research Is Maintained at Buy by Canaccord Genuity, from 9:31AM ET on Monday Nov 18, 2024 by Dow Jones
9:31AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 14, 2024
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
7:00AM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GH Research PLC | 482.8M | 0.0x | --- |
Celcuity Inc | 477.1M | -4.9x | --- |
Kalvista Pharmaceuticals Inc | 495.2M | -2.9x | --- |
Terns Pharmaceuticals Inc | 499.4M | -5.4x | --- |
ACELYRIN Inc | 465.5M | -1.7x | --- |
Alumis Inc | 511.4M | -2.1x | --- |
Company Information
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Contact Information
- Headquarters
- Joshua Dawson House, Dawson StreetDublin, Ireland D02 RY95
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Florian Schonharting
- Chief Executive Officer
- Velichka Valcheva
- Non-Executive Independent Vice Chairman of the Board
- Michael Forer
- Vice President - Finance
- Julie Ryan
- Managing Director, Ireland
- Magnus Halle
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $482.8M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 52.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | --- |
Book Value | $4.21 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
